Regeneron's Ronapreve Antibody Cocktail (casirivimab and imdevimab) Receives MHLW's Approval for the Treatment of Mild to Moderate COVID-19
Shots:
- The approval is based on the results from a P-III trial evaluating Ronapreve (casirivimab and imdevimab) in high-risk non-hospitalized patients with COVID-19
- The results showed a reduction in the risk of hospitalization or death by 70% in addition to the results from a P-I trial that demonstrated the safety- tolerability & PK in Japanese patients
- This marks the first time the Ab cocktail- known as REGEN-COV in the US and Ronapreve in other countries- has received a full approval to treat COVID-19
Ref: Prnewswire | Image: Fierce Pharma
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com